$BDTX

Black Diamond Therapeutics reported positive Phase 2 data for its lung cancer drug, silevertinib, showing a median progression-free survival of 15.2 months in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations. The data also indicated a 60% objective response rate and an 86% central nervous system response rate. The company plans to discuss a pivotal development plan with the FDA, noting the tolerability profile was manageable with dose adjustments.